ReviewHuman vaccines & immunotherapeutics2018
Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 58 citations in OpenAlex.
- BCG immunisation through intranasal instillation protects mice against Streptococcus pneumoniae infection by enhancing alveolar macrophage activity.Scientific reports · 2026Article
- Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis.American journal of preventive medicine · 2026Article
- Article
- Bioinformatic evaluation of ClpP as a vaccine target in Streptococcus pneumoniae.Biotechnology letters · 2026Article
- Molecular Characterization ofMicroorganisms · 2026Article
- A multivalent capsule vaccine protects against Klebsiella pneumoniae bloodstream infections in healthy and immunocompromised mice.NPJ vaccines · 2025Article
- Article
- Article
- Alleviating penicillin-resistant Streptococcus pneumoniae‑induced lung epithelial cell injury: mechanistic insights into effects of the optimized combination of main components from Yinhuapinggan granules.BMC infectious diseases · 2025Article
- Biocompatible glycolipid derived from bhilawanol as an antibiofilm agent and a promising platform for drug delivery.RSC medicinal chemistry · 2025Article
- Article
- Prevalence, spatial distribution and determinants of complete childhood pneumococcal conjugate vaccination in Ethiopia: spatial and multilevel analyses.BMC public health · 2024Article
- Time-resolved RNA-seq analysis to unravel theMicrobiology spectrum · 2024Article
- Importance of NK Cells in Cellular and Humoral Responses Triggered by Pneumococcus Vaccination.International archives of allergy and immunology · 2024Article
- Emerging vaccine strategies against the incessant pneumococcal disease.NPJ vaccines · 2023Review
- Prevalence and Homology of the Pneumococcal Serine-Rich Repeat Protein at the Global Scale.Microbiology spectrum · 2023Article
- Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development.F1000Research · 2023Review
- Editorial: Emerging infections in children.Frontiers in pediatrics · 2023Article
- Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.Vaccine · 2022Article
- Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Streptococcus pneumoniae is a major human bacterial pathogen responsible for millions of deaths each year and significantly more illnesses worldwide. With over 90 different serotypes, providing effective vaccine programs has been a continuing challenge. Since 1983, the world has been introduced to four different pneumococcal vaccines (PPSV23, PCV7, PCV10, and PCV13) each with their own complications and successes. Since vaccination programs began, a decrease in the overall rate of pneumococcal pneumonia and associated diseases has been observed, notably in higher risk populations. However, with a decrease in incidence of vaccine type pneumococcal serotypes, increases in non-vaccine serotypes of the bacteria have been observed along with serotype switching. Additionally, a rise in antibiotic resistant strains of S. pneumoniae is noted. Here we discuss both the positive and negative clinical manifestations of pneumonia vaccine programs and discuss the challenges in pneumococcal vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.